Pharmaceutical Intermediate CAS 763113-22-0 Olaparib Raw Material Olaparib Powder Olaparib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Olaparib
• Product Name: Olaparib
• Name: Olaparib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: Olaparib
• Mf: C24h23fn4o3
• MW: 434.46
• Refractive Index: 1.702
• Density: 1.43
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Intermediate CAS 763113-22-0 Olaparib Raw Material Olaparib Powder Olaparib

Product Description

Product Details

Product Name	Olaparib
CAS NO.	763113-22-0
Purity	99%
Density	1.43
Appearance and shape	White powder

Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.

Application&Function

Olaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism. It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

Specification